Kazuo Umezawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2029042/publications.pdf

Version: 2024-02-01

159 papers 4,465 citations

33 h-index 138468 58 g-index

162 all docs 162 docs citations

162 times ranked 4544 citing authors

#	Article	IF	CITATIONS
1	Isolation of a Novel Tyrosine Kinase Inhibitor, Lavendustin A, from Streptomyces griseolavendus. Journal of Natural Products, 1989, 52, 1252-1257.	3.0	251
2	Inhibition of Tumor Necrosis Factor-α-induced Nuclear Translocation and Activation of NF-κB by Dehydroxymethylepoxyquinomicin. Journal of Biological Chemistry, 2002, 277, 24625-24630.	3.4	193
3	Suppression of Diabetes-Induced Retinal Inflammation by Blocking the Angiotensin II Type 1 Receptor or Its Downstream Nuclear Factor-κB Pathway. , 2007, 48, 4342.		177
4	Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 865-869.	2.2	164
5	Inhibition of RANKL-Induced Osteoclastogenesis by (â^')-DHMEQ, a Novel NF-κB Inhibitor, Through Downregulation of NFATc1. Journal of Bone and Mineral Research, 2004, 20, 653-662.	2.8	143
6	Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Letters, 1990, 260, 198-200.	2.8	124
7	Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-ÂB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood, 2005, 106, 2462-2471.	1.4	124
8	Inactivation of NF-κB Components by Covalent Binding of (â^')-Dehydroxymethylepoxyquinomicin to Specific Cysteine Residues. Journal of Medicinal Chemistry, 2008, 51, 5780-5788.	6.4	118
9	ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6584-6589.	7.1	97
10	Inhibition of tumor growth by NF-?B inhibitors. Cancer Science, 2006, 97, 990-995.	3.9	96
11	Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Research, 2003, 63, 107-10.	0.9	94
12	Induction of Thyroid Cancer Cell Apoptosis by a Novel Nuclear Factor κB Inhibitor, Dehydroxymethylepoxyquinomicin. Clinical Cancer Research, 2004, 10, 6821-6829.	7.0	87
13	Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. I. Taxonomy,isolation, and characterization Journal of Antibiotics, 1993, 46, 1342-1346.	2.0	86
14	Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clinical Cancer Research, 2005, 11, 1287-93.	7.0	81
15	Chloptosin, an Apoptosis-Inducing Dimeric Cyclohexapeptide Produced by Streptomyces. Journal of Organic Chemistry, 2000, 65, 459-463.	3.2	78
16	Polyoxypeptins A and B Produced byStreptomyces:Â Apoptosis-Inducing Cyclic Depsipeptides Containing the Novel Amino Acid (2S,3R)-3-Hydroxy-3-methylproline. Journal of Organic Chemistry, 1999, 64, 3034-3038.	3.2	74
17	Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-IºB inhibitor. Tetrahedron, 2004, 60, 7061-7066.	1.9	72
18	Novel Nuclear Factor κB Activation Inhibitor Prevents Inflammatory Injury in Unilateral Ureteral Obstruction. Journal of Urology, 2003, 169, 1559-1563.	0.4	70

#	Article	lF	Citations
19	Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Research and Therapy, 2005, 7, R1348.	3.5	69
20	Cyclopentabenzofuran Lignan Protein Synthesis Inhibitors from Aglaia odorata. Journal of Natural Products, 1996, 59, 650-652.	3.0	68
21	Promotion of Â-Cell Differentiation by Conophylline in Fetal and Neonatal Rat Pancreas. Diabetes, 2004, 53, 2596-2602.	0.6	59
22	In vivo antitumor activity of the NF-κB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis, 2005, 26, 1382-1388.	2.8	54
23	Molecular design and biological activities of protein-tyrosine phosphatase inhibitors., 2003, 99, 15-24.		50
24	Conophylline Suppresses Pancreatic Stellate Cells and Improves Islet Fibrosis in Goto-Kakizaki Rats. Endocrinology, 2012, 153, 621-630.	2.8	48
25	Molecular design and biological activities of NF-kappaB inhibitors. Molecules and Cells, 2002, 14, 163-7.	2.6	45
26	A Simple Method to Induce Differentiation of Murine Bone Marrow Mesenchymal Cells to Insulin-producing Cells Using Conophylline and Betacellulin-delta4. Endocrine Journal, 2008, 55, 535-543.	1.6	44
27	Conophylline Protects Cells in Cellular Models of Neurodegenerative Diseases by Inducing Mammalian Target of Rapamycin (mTOR)-independent Autophagy. Journal of Biological Chemistry, 2015, 290, 6168-6178.	3.4	44
28	Stimulation of ultraviolet-induced apoptosis of human fibroblast UVr-1 cells by tyrosine kinase inhibitors. FEBS Letters, 1999, 444, 173-176.	2.8	43
29	Antidiabetic effect of orally administered conophylline-containing plant extract on streptozotocin-treated and Goto-Kakizaki rats. Biomedicine and Pharmacotherapy, 2009, 63, 710-716.	5.6	40
30	Prevention of Cancer Cachexia by a Novel Nuclear Factor κB Inhibitor in Prostate Cancer. Clinical Cancer Research, 2005, 11, 5590-5594.	7.0	39
31	Determination of cathepsin V activity and intracellular trafficking by Nâ€glycosylation. FEBS Letters, 2012, 586, 3601-3607.	2.8	39
32	Suppression of cellular invasion by glybenclamide through inhibited secretion of plateletâ€derived growth factor in ovarian clear cell carcinoma ESâ€2 cells. FEBS Letters, 2012, 586, 1504-1509.	2.8	39
33	Aberrant Expression of NF-κB in Liver Fluke Associated Cholangiocarcinoma: Implications for Targeted Therapy. PLoS ONE, 2014, 9, e106056.	2.5	37
34	Akaterpin, a novel bioactive triterpene from the marine sponge Callyspongia sp Tetrahedron Letters, 1997, 38, 1201-1202.	1.4	36
35	Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an lκBα-independent manner. Molecular Cancer Therapeutics, 2005, 4, 1114-1120.	4.1	35
36	Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer. BMC Cancer, 2015, 15, 324.	2.6	35

3

#	Article	IF	Citations
37	Inhibition of Acidic Sphingomyelinase by Xanthone Compounds Isolated from (i) Garcinia Speciosa (i). Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 129-138.	0.5	34
38	Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-ÂB, on glioblastoma. Neuro-Oncology, 2012, 14, 19-28.	1.2	34
39	Novel approaches to target NF- $\hat{\mathbb{P}}$ B and other signaling pathways in cancer stem cells. Advances in Biological Regulation, 2014, 56, 108-115.	2.3	33
40	Simultaneous and multi-point measurement of ammonia emanating from human skin surface for the estimation of whole body dermal emission rate. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1053, 60-64.	2.3	33
41	Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. Biochemical and Biophysical Research Communications, 2010, 403, 154-159.	2.1	32
42	Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone. Inflammation Research, 2011, 60, 879-888.	4.0	31
43	Control of Allograft Rejection by Applying a Novel Nuclear Factor-κB Inhibitor, Dehydroxymethylepoxyquinomicin. Transplantation, 2006, 82, 1720-1727.	1.0	29
44	Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models. Human Cell, 2018, 31, 95-101.	2.7	29
45	Induction of Indoleamine 2, 3-Dioxygenase in Human Dendritic Cells by a Cholera Toxin B Subunit—Proinsulin Vaccine. PLoS ONE, 2015, 10, e0118562.	2.5	28
46	Biosynthesis of polyoxypeptin A: novel amino acid 3-hydroxy-3-methylproline derived from isoleucine. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 1550-1553.	1.3	27
47	NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Arthritis Research and Therapy, 2007, 9, R97.	3.5	27
48	Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review. International Journal of Molecular Sciences, 2018, 19, 729.	4.1	26
49	Synthesis and biological evaluation on novel analogs of 9-methylstreptimidone, an inhibitor of NF-κB. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1726-1728.	2.2	25
50	Involvement of DNA binding domain in the cellular stability and importin affinity of NF-κB component RelB. Organic and Biomolecular Chemistry, 2012, 10, 3053.	2.8	25
51	Isolation of a novel substrate-competitive tyrosine kinase inhibitor, desmal, from the plant Desmos chinensis. FEBS Letters, 1993, 320, 169-172.	2.8	24
52	Inhibition of Cyclin D1 Expression and Induction of Apoptosis by Inostamycin in Small Cell Lung Carcinoma Cells. Japanese Journal of Cancer Research, 1998, 89, 315-322.	1.7	23
53	Strategic targeting of the PI3K–NFΰB axis in cisplatin-resistant NSCLC. Cancer Biology and Therapy, 2014, 15, 1367-1377.	3.4	23
54	Conophylline inhibits high fat diet-induced non-alcoholic fatty liver disease in mice. PLoS ONE, 2019, 14, e0210068.	2.5	23

#	Article	IF	CITATIONS
55	Conophylline suppresses hepatic stellate cells and attenuates thioacetamideâ€induced liver fibrosis in rats. Liver International, 2014, 34, 1057-1067.	3.9	22
56	Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response. Cell Death and Disease, 2016, 7, e2469-e2469.	6.3	22
57	Inhibition of MMP-2-mediated cellular invasion by NF-κB inhibitor DHMEQ in 3D culture of breast carcinoma MDA-MB-231 cells: A model for early phase of metastasis. Biochemical and Biophysical Research Communications, 2017, 485, 76-81.	2.1	22
58	Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer. Clinical and Experimental Metastasis, 2013, 30, 381-392.	3.3	21
59	Caspase-3 Activation Is Not Responsible for Vinblastine-induced Bcl-2 Phosphorylation and G2/M Arrest in Human Small Cell Lung Carcinoma Ms-1 Cells. Japanese Journal of Cancer Research, 1998, 89, 940-946.	1.7	20
60	Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-κB inhibitor DHMEQ. Microbes and Infection, 2008, 10, 748-756.	1.9	20
61	Efficient synthesis of ($\hat{A}\pm$)-parasitenone, a novel inhibitor of NF- \hat{I}^0 B. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5383-5386.	2.2	19
62	Efficient Cellular Uptake of the Novel NF-κB Inhibitor (â^')-DHMEQ and Irreversible Inhibition of NF-κB in Neoplastic Cells. Oncology Research, 2009, 18, 529-535.	1.5	19
63	Conophylline inhibits non-alcoholic steatohepatitis in mice. PLoS ONE, 2017, 12, e0178436.	2.5	19
64	Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor/receptor gene expression in human gastric carcinoma cells. International Journal of Cancer, 1991, 47, 938-942.	5.1	18
65	Isolation of Heptadepsin, a Novel Bacterial Cyclic Depsipeptide that Inhibits Lipopolysaccharide Activity. Chemistry and Biology, 2004, 11, 1059-1070.	6.0	18
66	Donor Pretreatment with DHMEQ Improves Islet Transplantation. Journal of Surgical Research, 2010, 163, e23-e34.	1.6	18
67	Growth Inhibitory Effects of Dipotassium Glycyrrhizinate in Glioblastoma Cell Lines by Targeting MicroRNAs Through the NF-κB Signaling Pathway. Frontiers in Cellular Neuroscience, 2019, 13, 216.	3.7	18
68	Potent Cytotoxic Effect of a Novel Nuclear Factor-κB Inhibitor Dehydroxymethylepoxyquinomicin on Human Bladder Cancer Cells Producing Various Cytokines. Urology, 2010, 75, 805-812.	1.0	17
69	Inhibition of MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ in Mast Cells. International Archives of Allergy and Immunology, 2015, 166, 84-90.	2.1	17
70	Induction of morphological change by tyrosine kinase inhibitors in Rous sarcoma virus-transformed rat kidney cells. FEBS Letters, 1991, 279, 132-136.	2.8	16
71	Synthesis and Structure–Activity Relationship of Dehydroxymethylepoxyquinomicin Analogues as Inhibitors of NF-κB Functions. Bioorganic and Medicinal Chemistry, 2002, 10, 3933-3939.	3.0	16
72	Inhibition of inflammatory mediator secretion by (\hat{a} °)-DHMEQ in mouse bone marrow-derived macrophages. Biomedicine and Pharmacotherapy, 2009, 63, 351-358.	5 . 6	16

#	Article	IF	CITATIONS
73	The NF- $\hat{I}^{\circ}B$ inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma. Cancer Letters, 2014, 349, 26-34.	7.2	16
74	Inhibition of epidermal growth factor receptor functions by tyrosine kinase inhibitors in NIH3T3 cells. FEBS Letters, 1992, 314, 289-292.	2.8	15
75	Unusual intramolecular Nâ†'O acyl group migration occurring during conjugation of (â^')-DHMEQ with cysteine. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5380-5382.	2.2	15
76	Determination of topological structure of ARL6ip1 in cells: Identification of the essential binding region of ARL6ip1 for conophylline. FEBS Letters, 2013, 587, 3656-3660.	2.8	15
77	Efficacy of DHMEQ, a NF-κB Inhibitor, in Islet Transplantation. Transplantation, 2013, 96, 454-462.	1.0	15
78	Amelioration of Severe TNBS Induced Colitis by Novel AP-1 and NF- $\langle i \rangle \hat{l}^2 \langle i \rangle$ B Inhibitors in Rats. Scientific World Journal, The, 2014, 2014, 1-8.	2.1	15
79	Inhibition of cellular inflammatory mediator production and amelioration of learning deficit in flies by deep sea Aspergillus-derived cyclopenin. Journal of Antibiotics, 2020, 73, 622-629.	2.0	15
80	Chemoenzymatic synthesis of (2S,3S,4S)-form, the physiologically active stereoisomer of dehydroxymethylepoxyquinomicin (DHMEQ), a potent inhibitor on NF-κB. Tetrahedron, 2010, 66, 7083-7087.	1.9	14
81	Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-κB inhibition. Journal of Allergy and Clinical Immunology, 2010, 126, 400-403.	2.9	14
82	Effect of a Novel Nuclear Factor-κB Activation Inhibitor on Renal Ischemia-Reperfusion Injury. Transplantation, 2013, 96, 863-870.	1.0	14
83	External application of NF-κB inhibitor DHMEQ suppresses development of atopic dermatitis-like lesions induced with DNCB/OX in BALB/c mice. Immunopharmacology and Immunotoxicology, 2017, 39, 157-164.	2.4	14
84	Inhibition of matrix metalloproteinase expression and cellular invasion by NF-κB inhibitors of microbial origin. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140412.	2.3	14
85	Long-lasting Accumulation of Vinblastine in Inostamycin-treated Multidrug-resistant KB Cells. Japanese Journal of Cancer Research, 1991, 82, 1160-1164.	1.7	13
86	Potentiation of Paclitaxel Cytotoxicity by Inostamycin in Human Small Cell Lung Carcinoma, Ms-1 Cells. Japanese Journal of Cancer Research, 1998, 89, 970-976.	1.7	13
87	Novel approaches to target cancer initiating cells–Eliminating the root of the cancer. Advances in Biological Regulation, 2012, 52, 249-264.	2.3	13
88	Migracins A and B, new inhibitors of cancer cell migration, produced by Streptomyces sp Journal of Antibiotics, 2013, 66, 225-230.	2.0	13
89	Isolation of a novel paxilline analog pyrapaxilline from fungus that inhibits LPS-induced NO production. Journal of Antibiotics, 2014, 67, 787-790.	2.0	13
90	Inhibition of Canonical NF-κB Nuclear Localization by (â^')-DHMEQ via Impairment of DNA Binding. Oncology Research, 2015, 22, 105-115.	1.5	13

#	Article	IF	Citations
91	Anti-Inflammatory Effect of Dehydroxymethylepoxyquinomicin, a Nuclear factor–κB Inhibitor, on Endotoxin-Induced Uveitis in Rats In vivo and In vitro. Ocular Immunology and Inflammation, 2020, 28, 240-248.	1.8	13
92	Conophylline Inhibits Hepatocellular Carcinoma by Inhibiting Activated Cancer-associated Fibroblasts Through Suppression of G Protein–coupled Receptor 68. Molecular Cancer Therapeutics, 2021, 20, 1019-1028.	4.1	13
93	Inhibition of NF-Kappa B Activation by 9-Methylstreptimidone Isolated from Streptomyces. Heterocycles, 2006, 69, 377.	0.7	13
94	Inhibition of NF-Kappa B Activation by Penicillic Acid and Dihydropenicillic Acid Isolated from Fungi. Heterocycles, 2008, 76, 1561.	0.7	13
95	Chemoenzymatic synthesis of (2R,3R,4R)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2. Organic and Biomolecular Chemistry, 2011, 9, 4635.	2.8	12
96	Enteroendocrine cells, stem cells and differentiation progenitors in rats with TNBS-induced colitis. International Journal of Molecular Medicine, 2016, 38, 1743-1751.	4.0	12
97	Isolation and Characterization of New Anti-Inflammatory and Antioxidant Components from Deep Marine-Derived Fungus Myrothecium sp. Bzo-l062. Marine Drugs, 2020, 18, 597.	4.6	12
98	Synthesis of sugar-modified derivatives of the unusual nucleoside oxanosine and its carbocyclic analogs as potential inhibitors of HIV. Journal of the Chemical Society, Perkin Transactions $1,2001,$, $298-304$.	1.3	11
99	Preparation of conophylline affinity nano-beads and identification of a target protein. Bioorganic and Medicinal Chemistry, 2009, 17, 6188-6195.	3.0	11
100	Rational design, synthesis and in vitro evaluation of novel exo-methylene butyrolactone salicyloylamide as NF-κB inhibitor. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 562-566.	2.2	11
101	Inostamycin, an Inhibitor of P-Glycoprotein Function, Interacts Specifically with Phosphatidylethanolamine. Japanese Journal of Cancer Research, 1995, 86, 873-878.	1.7	10
102	Anoikis Induction and Inhibition of Peritoneal Metastasis of Pancreatic Cancer Cells by a Nuclear Factor-ÎB Inhibitor, (â^')-DHMEQ. Oncology Research, 2014, 21, 333-343.	1.5	10
103	Poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2662-2673.	4.1	10
104	A nuclear factor-l ^o B inhibitor, dehydroxymethylepoxyquinomicin, ameliorates GVHD in allogeneic bone marrow transplantation. Immunobiology, 2015, 220, 1059-1066.	1.9	10
105	Effects of AP-1 and NF-κB inhibitors on colonic endocrine cells in rats with TNBS-induced colitis. Molecular Medicine Reports, 2016, 14, 1515-1522.	2.4	10
106	Anti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats. International Journal of Molecular Medicine, 2016, 37, 1457-1464.	4.0	10
107	Treatment with novel AP-1 and NF-κB inhibitors restores the colonic endocrine cells to normal levels in rats with DSS-induced colitis. International Journal of Molecular Medicine, 2016, 37, 556-564.	4.0	10
108	Inhibition of Cellular and Animal Inflammatory Disease Models by NF-κB Inhibitor DHMEQ. Cells, 2021, 10, 2271.	4.1	10

7

#	Article	IF	Citations
109	Induction of Apoptosis in Human Pancreatic Carcinoma Cells by a Synthetic Bleomycin-like Ligand. Japanese Journal of Cancer Research, 1998, 89, 947-953.	1.7	9
110	Synthesis of the indole core structures of conophylline. Journal of Heterocyclic Chemistry, 2008, 45, 1803-1808.	2.6	9
111	NF- $\hat{\mathbb{I}}^2$ B and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells. Life Sciences, 2020, 262, 118548.	4.3	9
112	Anticancer Activity of Novel NF-B Inhibitor DHMEQ by Intraperitoneal Administration. Oncology Research, 2020, 28, 541-550.	1.5	9
113	Immunosuppressive Effects of DTCM-G, a Novel Inhibitor of the mTOR Downstream Signaling Pathway. Transplantation, 2013, 95, 542-550.	1.0	8
114	Inhibition of receptor activator of nuclear factor- B ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB. Immunology Letters, 2014, 161, 31-37.	2.5	8
115	Inhibition of RANKL- and LPS-induced osteoclast differentiations by novel NF-κB inhibitor DTCM-glutarimide. International Immunopharmacology, 2015, 25, 162-168.	3.8	8
116	Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis. Molecular Medicine Reports, 2017, 15, 2106-2112.	2.4	8
117	Novel p-terphenyl glycoside with a rare 2,6-dideoxyhexopyranose moiety from Actinomycete strain SF2911 that inhibits cancer cell migration. Journal of Antibiotics, 2017, 70, 987-990.	2.0	8
118	NFâ€ÎºB inhibitor DHMEQ inhibits titanium dioxide nanoparticleâ€'induced interleukinâ€'1κ production: Inhibition of the PM2.5â€'induced inflammation model. Molecular Medicine Reports, 2018, 18, 5279-5285.	2.4	8
119	Inhibition of IGF-1-Mediated Cellular Migration and Invasion by Migracin A in Ovarian Clear Cell Carcinoma Cells. PLoS ONE, 2015, 10, e0137663.	2.5	8
120	Peritoneal NF-κB as a Possible Molecular Target for Suppression of Various Cancers and Inflammation. Forum on Immunopathological Diseases and Therapeutics, 2013, 4, 63-77.	0.1	8
121	Antiâ€'inflammatory effects of the NFâ€'κB inhibitor dehydroxymethylepoxyquinomicin on ARPEâ€'19 cells. Molecular Medicine Reports, 2020, 22, 582-590.	2.4	8
122	Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. International Journal of Oncology, 2006, 28, 841-6.	3.3	8
123	Apoptosis in Mouse Amniotic Epithelium Is Induced by Activated Macrophages Through the TNF Receptor Type 1/TNF Pathway. Biology of Reproduction, 2011, 84, 248-254.	2.7	7
124	Inhibition of NF-kappaB with Dehydroxymethylepoxyquinomicin modifies the function of human peritoneal mesothelial cells. American Journal of Translational Research (discontinued), 2016, 8, 5756-5765.	0.0	7
125	A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 871, 32-36.	2.3	6
126	Involvement of conserved tryptophan residues for secretion of TIMP-2. Oncology Letters, 2014, 7, 631-634.	1.8	6

#	Article	IF	CITATIONS
127	Inhibition of NO-induced β-cell death by novel NF-κB inhibitor (âˆ')-DHMEQ via activation of Nrf2–ARE pathway. Biochemical and Biophysical Research Communications, 2013, 433, 181-187.	2.1	5
128	Activation of apoptosis by caspase-3-dependent specific RelB cleavage in anticancer agent-treated cancer cells: Involvement of positive feedback mechanism. Biochemical and Biophysical Research Communications, 2015, 456, 810-814.	2.1	5
129	Isolation of ketomycin from Actinomycetes as an inhibitor of 2D and 3D cancer cell invasion. Journal of Antibiotics, 2019, 72, 148-154.	2.0	5
130	Virucidal effect of monogalactosyl diacylglyceride from a green microalga, Coccomyxa sp. KJ, against clinical isolates of SARSâ€CoVâ€2 as assessed by a plaque assay. Journal of Clinical Laboratory Analysis, 2021, , e24146.	2.1	5
131	Biosynthesis of the Lipophilic Side Chain in the Cyclic Hexadepsipeptide Antibiotic IC101. Journal of Natural Products, 2002, 65, 1953-1955.	3.0	4
132	Comparison of anti-atopic dermatitis activities between DHMEQ and tacrolimus ointments in mouse model without stratum corneum. International Immunopharmacology, 2019, 71, 43-51.	3.8	4
133	Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model. BMC Pharmacology & Dixicology, 2020, 21, 60.	2.4	4
134	Clinical application of ammonia emanating from severe burn patients during critical care. Journal of Japan Association on Odor Environment, 2016, 47, 421-429.	0.0	4
135	Herbimycin A Suppresses the Reduction of Gap-junctional Intercellular Communication Induced by Tumor-promoting Phorbol Ester in 3T3-L1 Cells. Japanese Journal of Cancer Research, 1989, 80, 855-860.	1.7	3
136	Screening of new bioactive metabolites for diabetes therapy. Internal and Emergency Medicine, 2013, 8, 57-59.	2.0	3
137	Inhibition of NF-κB and Cellular Invasion by Novel Flavonoid Dismal in Ovarian Carcinoma Cells. Heterocycles, 2016, 92, 353.	0.7	3
138	Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease. Inflammation Research, 2016, 65, 245-260.	4.0	3
139	Cellular Signal Transductions and Their Inhibitors Derived from Deep-Sea Organisms. Marine Drugs, 2021, 19, 205.	4.6	3
140	What does human skin gas analysis work for?. Journal of Japan Association on Odor Environment, 2017, 48, 410-417.	0.0	3
141	Synthesis and Inhibitory Activity Against Phosphatidylinositol 4-Kinase of Echiguanine Analogs. Nucleosides & Nucleotides, 1999, 18, 713-714.	0.5	2
142	Activation of Akt involves resistance to NF- \hat{P} B inhibition and abrogation of both triggers synergistic apoptosis in lung adenocarcinoma cells. Lung Cancer, 2014, 83, 139-145.	2.0	2
143	Design and synthesis of 15-deoxyspergualin–biotin conjugates as novel binding probes for target protein screening. Journal of Antibiotics, 2016, 69, 574-578.	2.0	2
144	Identification of poly(rC) binding protein 2 (PCBP2) as a target protein of immunosuppressive agent 15-deoxyspergualin. Biochemical and Biophysical Research Communications, 2016, 476, 445-449.	2.1	2

9

#	Article	IF	CITATIONS
145	Microbial Secondary Metabolites Inhibiting Oncogene Functions Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 1991, 49, 1062-1069.	0.1	2
146	Intravenous Administration of Dehydroxymethylepoxyquinomicin With Polymer Enhances the Inhibition of Pancreatic Carcinoma Growth in Mice. Anticancer Research, 2021, 41, 6003-6012.	1.1	2
147	Exploratory data analysis for medical data using interactive data visualization. , 2016, , .		1
148	Isolation, Synthesis, and Biological Activities of Signal Transduction Inhibitors Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 1996, 54, 1067-1075.	0.1	1
149	Prebiotic effect of lactulose on ammonia emanating from human skin surface. Journal of Japan Association on Odor Environment, 2020, 51, 338-345.	0.0	1
150	Visualization system for analyzing regional characteristics of Utstein data., 2017,,.		0
151	Synergistic effect of 17-allylamino-17-demethoxygeldanamycin with dehydroxymethylepoxyquinomicin on the human anaplastic thyroid carcinoma cell line KTC2. Archives of Biological Sciences, 2021, 73, 31-38.	0.5	O
152	CP8-9 NF- \langle sub> $\hat{l}^2\langle$ sub>B function inhibitor, DHMEQ as a treatment option for advanced urological cancer. Japanese Journal of Urology, 2004, 95, 163.	0.1	0
153	Microenvironmental Up-Regulation of NF-kB Activity Via P65-Dependent and Independent Pathways in a Bioimaging Model of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Blood, 2007, 110, 723-723.	1.4	O
154	Nuclear Factor kappa B (NFkB) Inhibition Improves Vascular Function in Type 2 Diabetic Mice. FASEB Journal, 2012, 26, .	0.5	0
155	Inhibition of NF-κB Activation Augments the Effect of 5-Azacytidine On Acute Myeloid Leukemia Cell Line. Blood, 2012, 120, 1369-1369.	1.4	0
156	Potential of NF-κB Inhibition in the Treatment of Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3625-3625.	1.4	0
157	Environmental odors in the clinical laboratory of a hospital. Indoor Environment, 2018, 21, 139-143.	0.1	0
158	Importance of Novel Intraperitoneal Therapy of NF-kappa B Inhibitor DHMEQ. Kreativnaâ Hirurgiâ I Onkologiâ, 2019, 9, 87-88.	0.3	0
159	DHMEQ enhances the cytotoxic effect of cisplatin and carboplatin in ovarian cancer cell lines American Journal of Cancer Research, 2021, 11, 6024-6041.	1.4	0